FDA warns Fallien over unapproved OTC sunscreen foam TiZO SHEERFOAM SPF 30 sold without required authorization.
What happened
On May 14, 2025, FDA reviewed the company’s website and Instagram and Facebook pages, which direct consumers to the website to buy TiZO SHEERFOAM SPF 30. FDA treated the product as an OTC sunscreen drug because its labeling says it helps prevent sunburn. FDA found no approved application for the product and said the foam/mousse dosage form is not authorized for marketing under the OTC sunscreen order M020.
What FDA found
The product is a drug because its labeling says it helps prevent sunburn and affects the body.
FD&C Act §201(g)(1)(B)-(C), 21 U.S.C. 321(g)(1)(B)-(C)The OTC sunscreen is misbranded because it is marketed without an FDA-approved application and does not meet section 505G requirements.
FD&C Act §502(ee), 21 U.S.C. 352(ee); §505G, 21 U.S.C. 355hThe foam/mousse dosage form is not among the sunscreen dosage forms allowed under M020, and no final order authorizes foam sunscreens.
FD&C Act §505G(m)(2), 21 U.S.C. 355h(m)(2); OTC Monograph M020Shipping the misbranded drug in interstate commerce violates the law.
FD&C Act §301(a), 21 U.S.C. 331(a)
What FDA wants
FDA asks the company to notify it in writing within 15 working days of steps taken to correct the violations, prevent recurrence, and provide related documentation. If the company believes there is no violation, it must send its reasoning and supporting information.
Who should pay attention
- other OTC sunscreen brands selling nonstandard dosage forms
- contract manufacturers and marketers of foam or mousse sunscreens
- retailers and distributors selling OTC sunscreen drug products
This is a summary. Read the original letter on fda.gov.